MedTrace Logo

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

NCT04234594 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2020-05-19

No results posted yet for this study

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.

Conditions

  • Healthy Males

Interventions

DRUG

QL1203

6 mg/kg intravenous (IV) infusion only once，on the first day.

DRUG

Vectibix®

6 mg/kg intravenous (IV) infusion only once，on the first day.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weiwei Ouyang, Professor · Cancer Hospital of Guizhou Province

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04234594 on ClinicalTrials.gov